Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Coya Therapeutics' Gains from Investment Securities rose 3525.97% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 3525.97%. This contributed to the annual value of $2.2 million for FY2024, which is 9650.56% up from last year.
  • According to the latest figures from Q3 2025, Coya Therapeutics' Gains from Investment Securities is $3.0 million, which was up 3525.97% from $3.0 million recorded in Q2 2025.
  • Coya Therapeutics' 5-year Gains from Investment Securities high stood at $3.0 million for Q3 2025, and its period low was $8249.0 during Q1 2024.
  • Moreover, its 4-year median value for Gains from Investment Securities was $1.1 million (2023), whereas its average is $1.3 million.
  • In the last 5 years, Coya Therapeutics' Gains from Investment Securities tumbled by 5000.61% in 2024 and then surged by 87054.19% in 2025.
  • Coya Therapeutics' Gains from Investment Securities (Quarter) stood at $478570.0 in 2022, then skyrocketed by 136.99% to $1.1 million in 2023, then skyrocketed by 96.95% to $2.2 million in 2024, then skyrocketed by 35.26% to $3.0 million in 2025.
  • Its Gains from Investment Securities was $3.0 million in Q3 2025, compared to $3.0 million in Q2 2025 and $80060.0 in Q1 2025.